A Managerial Perspective1

7/31/2019 A Managerial Perspective1

1/28

Management Perspective

BY: Muhammad Bilal Khawaja - 13893Muhammad Noman Khan - 13836

S.M. Zeeshan 13910

G l a x o S m i t h K l i n e


2/28

Agenda

Pakistan Pharmaceutical Industry

GSK at a glance

History

Market Share

Objectives Problems and issues

SWOT Analysis

Action programs

Action plans

Financial projections

Milestones

Controls


3/28

Pakistan Pharma Industry

Major Pharma Companies

Johnson & Johnson

Pfizer

GSK

Roche

Novartis

Sanofi-Aventis

Abbott Laboratories


4/28

GSK at a glance

As no. 1 pharmaceutical company in Pakistan

With mission

Do more | Feel better | Live longer

Deals in

PHARMACEUTICAL

BIOLOGICS VACCINES

CONSUMER HEALTHCARE COMPANY


5/28

VisionThe Opportunity to make a difference to the lives

of the billions of people

Values Transparency

Integrity

Respect for People

Patient Focus

GSK at a glance


6/28

GSK Products


7/28

History

1947 Glaxo operations organized in Pakistan

at Independence

1949 SK&F came to Pakistan under the name

of Pharmaco limited 1952 Glaxo became public limited.

1954 Beecham incorporated in Pakistan

1955 Glaxo established manufacturingfacilities in Pakistan.

1955 Wellcome incorporated in Pakistan


8/28

History

1956 Wellcome established manufacturing

facilities in Pakistan

1979 Wellcome Pakistan Became Public Limited

1996 Glaxo and Wellcome merged to becomeGlaxo Wellcome

2002 Glaxo Wellcome, Beecham And Sk&f

Integrated As a result Of Global Merger To

Form GlaxoSmithKline

2009 Stiefel (dermatological pharmaceutical)

was acquired by GlaxoSmithKline


9/28

Achievements

2005 Excellence Award in Best Practices by

Occupational, Health and safety by

Employers Federation of Pakistan

2006: 50 Star Rating from the Global

internal Audit, Highest in the Industry

2007: Most Prefered Pharmaceutical

Company, by Pakistan Society for Human

Resource Manager


10/28

Achievements

Also Received for Best Management

Practices by the management association

of Pakistan

2009: Annual Environment Excellence

Award in recognition of its policies on safe

guarding health


11/28

Market Share

Names Market ShareGSK 13.80%

Sanofi-Aventis 4.10%

Getz Pharma 3.90%

Abbott Lab 3.80%

Roche 3.10%

Merck 2.90%


12/28

Market Share


13/28

Objectives

Expansion

Consistent Price across the board

Research Based Product Launches

Growth with Sustainability


14/28

Organizational Chart


15/28

Problems and Issues

Increased Competition

Changing consumer profile

Rupee Depreciation

Decreasing Consumer Influence

Policies and Guidelines Implementations

Security Issue


16/28

SWOT Analysis

STRENGTHS

Strong infrastructure

Industry-leading early to mid-stage R&D pipeline

Life-cycle management strategies

Strong business fundamentals and robust balancesheet

Demonstrated ability to drive cost elimination


17/28

SWOT Analysis

WEAKNESSES

Mature portfolio of marketed products

High dependence on low growth/highly

competitive Failure of R&D pipeline


18/28

SWOT Analysis

OPPORTUNITIES

Potential for inspired R&D pipeline

Enhanced vaccine offering Movement into high growth oncology market

Movement into biologics

Continued cost elimination Strong cash position facilitates


19/28

SWOT Analysis

THREATS

Launch of new generics by competitors

Counterfeiting

Unethical practices by competitors

Pricing control

Changing Consumer Profile Decreasing consumer influence

Policies and Guidelines Implementations


20/28

Competitive Forces


21/28

External Environment

Competitive Forces

Potential Development of Substitute Product

Bargaining Power of Supplier

Bargaining Power Of Consumers

Economic Forces

Social and Demographic Forces

Technological Forces

Political Forces


22/28

Action Programs

Developing strategies

Grow a diversified global business

Deliver more products of value Simplify the operating model

Create a culture of individual empowerment

Building trust


23/28

Action Plans

Implementation of generics in Pakistan

Launching new products

Futuristic plan

Focus on Research

Aggressive Marketing And Promotion

Traditional marketing Digital marketing


24/28

Financial Projections


25/28

Milestones

Augmentin became the first ever 3 billion products

in Pakistan during 2011.

GSK is ranked no.1 in terms of value

GSK is ranked no.1 in terms of volume GSK is ranked no.1 in terms of prescription

GSK has 8 products in the top 20 products in terms

of value.


26/28

Milestones

GSK has 10 products in the top 20 products in

terms of volume

GSK has 6 products in the top 20 products in terms

of prescription Approx. 600,000 prescriptions are written every

day for GSK products in Pakistan

Approx. 10 million GSK tablets are consumed each

day in Pakistan

Approx. 4.3 million teaspoons of GSK products are

consumed each day


27/28

Controls

Feedback Mechanism

360 Degree Review Process

Control Mechanism

Internal Control

Audit Committee

Corporate Governance

Financial Reporting


28/28

Questions

Documents

A Managerial Perspective1